Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
News|Articles|June 16, 2025
Daily Derm Times: June 16, 2025
Author(s)Emma Andrus, Editor
Listen
0:00 / 0:00
Key Takeaways
- AI tools like SkinGPT enhance personalized skin care by simulating results and integrating clinical data with patient insights.
- Generalized pustular psoriasis patients face up to a five-fold higher mortality risk, highlighting the need for effective management.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
Advertisement
To stay up-to-date with the latest dermatology news, sign up to receive our
Beyond the Label: How AI Tools Such as SkinGPT Enhance Skin Care Understanding
SkinGPT by Haut.AI uses AI to visually simulate skin care results, empowering inclusive, personalized skin care and bridging clinical data with patient insight.
Data Show Up to 5-Fold Higher Mortality Risk in Patients With Generalized Pustular Psoriasis
New research reveals that early discontinuation of adjuvant immunotherapy for melanoma does not lead to worse outcomes.
Nearly Half of Patients Respond to Ritlecitinib for Alopecia Areata, With Most Sustaining Results
Subgroups more likely to respond included women and those with shorter-duration, less extensive hair loss.
SLIDESHOW: Recent Data from LEO Pharma on Chronic Hand Eczema
Global studies from LEO Pharma highlight the diagnostic gaps, quality-of-life burdens, and treatment landscape for patients with CHE.
Advertisement
Related to this article
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
New indications for superficial basal cell carcinoma and adolescent alopecia areata expanded treatment options, while psoriasis and rare disease candidates advanced through FDA review.
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance
5